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Aspirin resistance and ischemic stroke outcome: Fact or fiction?Stroke is a major cause of morbidity and mortality in
Taiwan, where it is the leading cause of disability1 and the
third leading cause of death.2 Close to a quarter of the nearly
800,000 strokes that occur annually in the United States are
recurrent events.3 Thus, it is important to reduce the risk of
recurrent stroke in patients that have suffered a prior stroke
event.
Platelet activation plays a vital role in arterial thrombosis,
such as in cardiovascular disease, peripheral arterial disease,
and ischemic stroke, for which such thrombosis accounts for
70% of the strokes in Taiwan.4 Arterial thrombosis is
commonly treated and prevented by administration of anti-
platelet agents. Of these, aspirin remains the most widely used
agent for the prevention of noncardioembolic ischemic
stroke.5 The relative risk reduction for recurrent stroke is 22%,
leaving some patients (30e40%) to develop new strokes
despite taking aspirin.6 Such recurrent events in aspirin-treated
patients represent a significant treatment challenge.
Aspirin works by irreversibly acetylating the cyclo-
oxygenase (COX)-1 enzyme, thus suppressing the formation
of thromboxane A2 (TXA2), a potent agonist of platelet
aggregation.
7 The term “aspirin resistance” (AR) has been
used to describe the various manifestations of aspirin’s
insufficient inhibitory effects on platelet function, due to AR
or persistently high platelet reactivity in laboratory tests, such
as short bleeding time and/or persistently high levels of TXA2
production.8,9 Patients are considered to have biochemical
(laboratory-defined) AR when their in vitro platelet reactivity
is not properly blocked despite the use of aspirin, and are
considered to have clinical AR or “treatment failure” when
thrombotic events occur even while they are taking aspirin.
The mechanisms underlying AR are uncertain. Several
pharmacodynamic and pharmacokinetic factors are likely to
play a role in the variability of platelet inhibition observed
with aspirin treatment, including bioavailability, patient
compliance, genetic polymorphisms, activation of alternate
platelet-stimulation pathways, accelerated platelet turnover,
and factors associated with antiplatelet resistance.8e10
The prevalence of biochemical AR in stroke patients is
highly variable, ranging from 3% to 85% in different studies.8
This high variance can be attributed, at least in part, to the use
of noncorrelated measurement techniques, such as the Platelet
Function Analyzer (PFA)-100 assay, the VerifyNowAspirin
assay, and light transmittance aggregometry (LTA).8 In theory,1726-4901/$ - see front matter Copyright  2012 Elsevier Taiwan LLC and the C
http://dx.doi.org/10.1016/j.jcma.2012.08.018assays that are directly related to COX-1 functionalitydsuch
as the generation of thromboxane B2 (TXB2, a stable metab-
olite of TXA2) in serum and arachidonic acid (AA)-induced
platelet aggregationdshould enable more accurate assessment
of aspirin efficacy.9
Serum TXB2 levels reflect the total capacity of platelets to
synthesize TXA2 ex vivo in response to various stimuli. The
rate of clinically significant residual TXB2 production is
extremely low in healthy individuals and cardiovascular
disease patients who are taking aspirin. Levels of the urinary
thromboxane metabolite (i.e., 11-dehydroTXB2) reflect in vivo
time-integrated TXA2 biosynthesis.
11 Assays of the urinary
metabolite are less specific than assays of COX-1-generated
TXA2, as about 30% of the urinary metabolite is derived
from COX-2 generated sources, which are independent of
platelets.
Other COX-1 activity-dependent tests of platelet function
measure changes in the light transmission of a platelet
suspension during aggregation in vitro.9,10 However, these
tests may not be specific for the effects of aspirin as platelets
can be activated by other factors besides stimulation of the
TXA2 receptor. In LTA, the most thoroughly evaluated light
transmission method for testing platelet function, changes in
light transmission produced by AA agonist-induced platelet
aggregation are measured. Although LTA is the historical gold
standard for examining the antiplatelet effects of aspirin and
remains the most widely used test for assessing platelet
function, it is labor-intensive and has yet to be strongly
correlated and standardized with other tests.
Several “point-of-care” assays have been developed to
reduce the laboratory requirement for LTA, including the
PFA-100, which uses less whole blood than LTA and has
a quick enough analysis time to be amenable to outpatient use.
The PFA-100 could be regarded as an in vitro bleeding time
recorder.12 It simulates an artificial vessel with a thrombo-
genic membrane coated with collagen and either epinephrine
or adenosine diphosphate. A constant negative pressure aspi-
rates anticoagulated blood through this faux-vessel until
a platelet plug forms. The time needed for blood flow to be
interrupted (closure time) is recorded. Although the PFA-100
is easy to use, it is sensitive to many variables, including
platelet count and presence of the von Willebrand factor,
which hinders its specificity as a tool with which to assess
aspirin efficacy.hinese Medical Association. All rights reserved.
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linked low platelet inhibition in patients exhibiting biochemical
AR to an increased risk for ischemic events. Twometa-analyses
focused on aspirin nonresponders identified by the PFA-100
method showed that PFA-100-defined aspirin nonresponders
were more likely to have vascular events than responders.13,14
In the current issue of the Journal of the Chinese Medical
Association, Lai et al report a relationship between biochemical
AR and functional outcome following an acute ischemic
stroke.15 Demographic data, vascular risk factors, and inflam-
matory biomarkers were analyzed prospectively in 269 patients.
Biochemical AR after 5 days of aspirin use was assessed using
a PFA-100 instrument equipped with an epinephrine/collagen
cartridge. Patients classified as having biochemical AR (n¼ 83;
30.9%) had poorer 30-day and 90-day functional outcomes (as
defined by modified Rankin Scale scores >2) than non-AR
patients. However, the effect did not remain significant when
the analysis was adjusted in consideration of other risk factors.
This seemingly contradictory result was explained by the
concomitant presence of inflammation/infection in acute
ischemic stroke overriding the AR effect. However, it is also
important to note that only short-term outcome data were
available, leaving the long-term effect of AR unknown.
A total of 1,276 acute ischemic stroke patients were
registered in the Taipei Veterans General Hospital stroke
databank from February 2009 to February 2011. Of these, 180
(14.1%) died within 1 year. Use of antiplatelet drugs after
discharge was associated with a better outcome (Yang et al,
unpublished data). Furthermore, in a population of over 20,000
registered stroke patients in the Taiwan Stroke Registry, use of
antithrombotic agents was associated with a better 6-month
functional outcome.4 Although AR was not tested in these
studies, it is clear that antiplatelet medication is a good
predictor of a better outcome after stroke. Well-defined, large-
scale prospective long-term follow-up trials are needed to
establish the role of AR in ischemic stroke in Taiwan and
elsewhere.
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